RTSAFE HOLDING LIMITED

RTsafe Holding Limited is a medical‑technology company dedicated to elevating safety and effectiveness in radiation oncology. By developing and commercialising cutting‑edge quality‑assurance tools, RTsafe enables personalised radiotherapy that strives for the “minimum‑achievable‑risk” treatment for each patient.

The flagship offering, the FDA‑cleared PseudoPatient® solution, provides a fully personalised dosimetry audit for brain‑tumour cases and has been recognised as one of the 100 most technologically significant products of 2019. Built on extensive research and dozens of scientific publications, the system delivers end‑to‑end quality assurance, helping clinicians, medical physicists, physicians and administrators reduce uncertainty and improve outcomes. RTsafe’s portfolio also includes comprehensive dosimetry audit services and bespoke phantom‑building support, all designed to make high‑precision radiotherapy accessible to millions of cancer patients worldwide.

Whether you are a patient seeking safer treatment, a medical professional aiming to enhance workflow, or a physicist focused on treatment accuracy, RTsafe’s innovative technologies are crafted to support every role in the radiotherapy pathway.